Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has shared an update.
ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for FY2024, showing a slight increase in net sales by 2.1% to 64,139 million yen. However, the company experienced a decline in operating profit and ordinary profit by 18.0% and 21.7%, respectively. The profit attributable to owners of the parent decreased significantly by 32.4%. Despite these declines, the company has increased its annual dividends per share from 40.00 yen to 55.00 yen, indicating a commitment to returning value to shareholders. Looking forward, ASKA forecasts a positive outlook for FY2025, with expected increases in net sales and profits, reflecting a strategic focus on growth and operational efficiency.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily engaged in the pharmaceutical industry. The company focuses on developing and marketing pharmaceutical products, contributing to healthcare advancements.
Average Trading Volume: 47,952
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen61.9B
For an in-depth examination of 4886 stock, go to TipRanks’ Stock Analysis page.